Ferrer expands Tyvaso® distribution agreement with United Therapeutics Corp for new indications in pulmonary diseases.

Ferrer expands distribution agreement with United Therapeutics Corp for Tyvaso® (treprostinil inhalation solution) to treat Pulmonary Hypertension-ILD & PAH. The expanded deal includes new potential indications for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis. Ferrer is appointed as the exclusive worldwide distributor, except in US, Canada, Japan, China, and Israel, with the drug currently in Phase 3 trials.

May 28, 2024
3 Articles